Metabolomic signatures of SSRI exposure during neural differentiation and correlation of lysophosphatidylcholines with early symptoms of neurodevelopmental disorders

BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are often prescribed during pregnancy. Epidemiological studies examining in-utero SSRI exposure and neurodevelopmental outcomes such as autism and ADHD have produced mixed results, in part due to challenges in accounting for underlying maternal mental health conditions and other confounding factors. The molecular pathways through which SSRIs may affect early neurodevelopment remain poorly understood.

via https://pubmed.ncbi.nlm.nih.gov/42150307/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1lqZ3NPYysePVKsoyz66mDSgu4veDGJwnUBS47TBQPoOuNZY5J&fc=None&ff=20260525011006&v=2.20.0